Abstract
Alzheimer’s disease is a brain disease that slowly destroys memory and thinking skills, and eventually, the ability to carry out the simplest tasks. It begins slowly and gets worse over time. The main risk factor for Alzheimer's disease is increased age. As a population ages, the frequency of Alzheimer's disease continues to increase. Currently, there is no cure. There are many compromises in the brain of an Alzheimer's patient. Essentially, three modifications occur: decrease of cholinergic impulse, increased toxic effects caused by ROS, and an inflammatory process in which amyloid plaque participates. This study is a mini-review of Alzheimer’s disease, and we report advances in the studies concerning enzymes, and substances or targets of these three processes. Our review was focused on a few biological pathways and involved in the pathophysiology of AD: cholinergic system; oxidative stress; beta-amyloid processing; insulin signaling. We analyzed a large body of evidence coming from biochemical studies and a series of compounds which act on these pathways as alternative treatments for the disease.
Keywords: Acetylcholinesterase, Alzheimer’s disease, Amyloid plaques, Cholinergic impulse, Dementia, ROS.
Letters in Drug Design & Discovery
Title:Biochemical Changes Evidenced in Alzheimer's Disease: A Mini-Review
Volume: 11 Issue: 2
Author(s): Luciana Scotti, Francisco Jaime Bezerra Mendonça Junior, Marcelo Sobral da Silva, Ivan R. Pitta and Marcus Tullius Scotti
Affiliation:
Keywords: Acetylcholinesterase, Alzheimer’s disease, Amyloid plaques, Cholinergic impulse, Dementia, ROS.
Abstract: Alzheimer’s disease is a brain disease that slowly destroys memory and thinking skills, and eventually, the ability to carry out the simplest tasks. It begins slowly and gets worse over time. The main risk factor for Alzheimer's disease is increased age. As a population ages, the frequency of Alzheimer's disease continues to increase. Currently, there is no cure. There are many compromises in the brain of an Alzheimer's patient. Essentially, three modifications occur: decrease of cholinergic impulse, increased toxic effects caused by ROS, and an inflammatory process in which amyloid plaque participates. This study is a mini-review of Alzheimer’s disease, and we report advances in the studies concerning enzymes, and substances or targets of these three processes. Our review was focused on a few biological pathways and involved in the pathophysiology of AD: cholinergic system; oxidative stress; beta-amyloid processing; insulin signaling. We analyzed a large body of evidence coming from biochemical studies and a series of compounds which act on these pathways as alternative treatments for the disease.
Export Options
About this article
Cite this article as:
Scotti Luciana, Jaime Bezerra Mendonça Junior Francisco, Sobral da Silva Marcelo, R. Pitta Ivan and Tullius Scotti Marcus, Biochemical Changes Evidenced in Alzheimer's Disease: A Mini-Review, Letters in Drug Design & Discovery 2014; 11 (2) . https://dx.doi.org/10.2174/15701808113109990063
DOI https://dx.doi.org/10.2174/15701808113109990063 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Microarray and Nanotechnology Applications of Functional Nanoparticles
Combinatorial Chemistry & High Throughput Screening Bench to Bedside Targeting of FLT3 in Acute Leukemia
Current Drug Targets Meet Our Editorial Board Member
Infectious Disorders - Drug Targets The Effects of Variants in the Parkin, PINK1, and DJ-1 Genes along with Evidence for their Pathogenicity
Current Protein & Peptide Science Epigenetic Modulation Using Small Molecules - Targeting Histone Acetyltransferases in Disease
Current Medicinal Chemistry STAT3 and Its Phosphorylation are Involved in HIV-1 Tat-Induced Transactivation of Glial Fibrillary Acidic Protein
Current HIV Research Rikkunshito and Ghrelin Secretion
Current Pharmaceutical Design How Do Microbubbles and Ultrasound Interact? Basic Physical, Dynamic and Engineering Principles
Current Pharmaceutical Design Inhibition of PI3K/mTOR Pathways with GDC-0980 in Pediatric Leukemia: Impact on Abnormal FLT-3 Activity and Cooperation with Intracellular Signaling Targets
Current Cancer Drug Targets Chronic Granulomatous Disease in Childhood
Current Pediatric Reviews DEFB1 5'UTR Polymorphisms Modulate the Risk of HIV-1 Infection in Mexican Women
Current HIV Research Canine Nutritional Model: Influence of Age, Diet, and Genetics on Health and Well-Being
Current Nutrition & Food Science Recent Developments in Targeting Bromodomain and Extra Terminal Domain Proteins for Cancer Therapeutics
Current Medicinal Chemistry Dental Caries and Vaccination Strategy against the Major Cariogenic Pathogen, Streptococcus mutans
Current Pharmaceutical Biotechnology Macrocyclic Inhibitors of Hsp90
Current Topics in Medicinal Chemistry Light Deficiency Confers Breast Cancer Risk by Endocrine Disorders
Recent Patents on Anti-Cancer Drug Discovery Capacity Building in Genomics Medicine and Molecular Diagnostics: The Case of Sri Lanka
Current Pharmacogenomics and Personalized Medicine Chronic Diseases and COVID-19: A Review
Endocrine, Metabolic & Immune Disorders - Drug Targets The Crosstalk between Gut Microbiota, Intestinal Immunological Niche and Visceral Adipose Tissue as a New Model for the Pathogenesis of Metabolic and Inflammatory Diseases: The Paradigm of Type 2 Diabetes Mellitus
Current Medicinal Chemistry Lactoferrin as a Natural Immune Modulator
Current Pharmaceutical Design